3.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$2.47
Aprire:
$2.61
Volume 24 ore:
35.65M
Relative Volume:
10.74
Capitalizzazione di mercato:
$330.19M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-2.1747
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
+46.15%
1M Prestazione:
+54.27%
6M Prestazione:
+173.48%
1 anno Prestazione:
+1.69%
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CABA
Cabaletta Bio Inc
|
3.61 | 225.92M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Ripresa | Jefferies | Buy |
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Will Cabaletta Bio Inc. see short term momentumOil Prices & Weekly Stock Performance Updates - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Cabaletta Bio’s Remarkable Surge: Positive Clinical Data and Elevated Price Targets - StocksToTrade
Cabaletta Bio Stock Price Rises After Positive Clinical Data Announcement - timothysykes.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Update - MarketBeat
Tools to assess Cabaletta Bio Inc.’s risk profile2025 Dividend Review & Free Real-Time Market Sentiment Alerts - newser.com
Jennison Associates LLC Boosts Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? - MSN
Can Cabaletta Bio Inc. stock maintain operating marginsEarnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Cabaletta Bio Stock Climbs Amid Positive Clinical Developments - StocksToTrade
Cabaletta Bio Poised for Growth Amid Positive Clinical Data Releases - timothysykes.com
Cabaletta Bio (NASDAQ:CABA) Price Target Raised to $30.00 - MarketBeat
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Weekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
CABA Stock: Cantor Fitzgerald Raises Price Target to $30, Mainta - GuruFocus
How Cabaletta Bio Inc. stock reacts to bond yieldsJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Comparing Cabaletta Bio Inc. in custom built stock radars2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - Insider Monkey
Is Cabaletta Bio Inc. stock attractive for long term wealth buildingEarnings Miss & Consistent Profit Trading Strategies - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsJuly 2025 Update & Safe Entry Point Alerts - newser.com
Applying sector rotation models to Cabaletta Bio Inc.July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
10 Best Stocks Under $3 to Invest In - Insider Monkey
Visualizing Cabaletta Bio Inc. stock with heatmaps2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Cabaletta Bio Updates on CD19-CAR T Therapy Progress - TipRanks
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
How Cabaletta Bio Inc. stock benefits from strong dollarPortfolio Gains Summary & Reliable Trade Execution Plans - fcp.pa.gov.br
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial - BioSpace
Cabaletta Bio stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Philippines
How Cabaletta Bio Inc. stock compares to growth peers2025 Technical Patterns & AI Powered Market Entry Strategies - fcp.pa.gov.br
What makes Cabaletta Bio Inc. stock attractive to growth fundsDollar Strength & High Accuracy Trade Alerts - fcp.pa.gov.br
Entry Recap: Can Cabaletta Bio Inc. stock rebound after recent weaknessJuly 2025 Institutional & Technical Buy Zone Confirmations - fcp.pa.gov.br
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):